PubRank

Yoshihiro Fujimura

Author PubWeight™ 69.55‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002 2.23
2 ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003 2.06
3 Autopsy case of sudden maternal death from thrombotic thrombocytopenic purpura. J Obstet Gynaecol Res 2012 1.96
4 Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005 1.85
5 SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection. Blood 2002 1.59
6 VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2003 1.55
7 Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008 1.45
8 Intravenous gamma globulin for thrombotic microangiopathy of unknown etiology. Pediatr Nephrol 2006 1.43
9 [Case of thrombotic thrombocytopenic purpura associated with clopidogrel]. Rinsho Shinkeigaku 2007 1.37
10 Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost 2009 1.33
11 Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006 1.28
12 Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol 2013 1.10
13 Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2003 1.10
14 Functional imaging of shear-dependent activity of ADAMTS13 in regulating mural thrombus growth under whole blood flow conditions. Blood 2007 1.07
15 Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012 1.06
16 Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion 2002 1.03
17 Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure. Nephrol Dial Transplant 2006 1.00
18 Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl 2009 1.00
19 Influenza A infection triggers thrombotic thrombocytopenic purpura by producing the anti-ADAMTS13 IgG inhibitor. Intern Med 2010 1.00
20 Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 2007 0.97
21 Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 2004 0.96
22 The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004 0.95
23 Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation. Int J Hematol 2014 0.95
24 Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol 2005 0.93
25 Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis. Scand J Gastroenterol 2008 0.91
26 Mural thrombus generation in type 2A and 2B von Willebrand disease under flow conditions. Blood 2002 0.90
27 Binding site on human von Willebrand factor of bitiscetin, a snake venom-derived platelet aggregation inducer. Biochemistry 2002 0.88
28 Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation. Heart Vessels 2008 0.88
29 Pivotal role of ADAMTS13 function in liver diseases. Int J Hematol 2010 0.87
30 Thrombotic thrombocytopenic purpura associated with pegylated-interferon alpha-2a by an ADAMTS13 inhibitor in a patient with chronic hepatitis C. Haematologica 2006 0.87
31 Adenovirus-mediated transfer of human placental ectonucleoside triphosphate diphosphohydrolase to vascular smooth muscle cells suppresses platelet aggregation in vitro and arterial thrombus formation in vivo. Circulation 2005 0.86
32 Ratio of von Willebrand factor propeptide to ADAMTS13 is associated with severity of sepsis. Shock 2013 0.85
33 Plasma levels of ADAMTS13 antigen determined with an enzyme immunoassay using a neutralizing monoclonal antibody parallel ADAMTS13 activity LevEls. Int J Hematol 2007 0.84
34 Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: relationship to endotoxemia. Alcohol Clin Exp Res 2009 0.84
35 Relation of CD39 to plaque instability and thrombus formation in directional atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol 2005 0.84
36 Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension. Pediatr Nephrol 2014 0.84
37 Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Thromb Res 2011 0.83
38 Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2007 0.81
39 Identification of epitopes on ADAMTS13 recognized by a panel of monoclonal antibodies with functional or non-functional effects on catalytic activity. Thromb Res 2012 0.81
40 Rapid Restoration of Thrombus Formation and High-Molecular-Weight von Willebrand Factor Multimers in Patients with Severe Aortic Stenosis After Valve Replacement. J Atheroscler Thromb 2016 0.81
41 Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin. Intern Med 2013 0.81
42 Ecto-nucleoside triphosphate diphosphohydrolase inhibits ATP- and ADP-induced vasoconstriction. Thromb Res 2007 0.80
43 Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol 2005 0.79
44 Human placental ectonucleoside triphosphate diphosphohydrolase gene transfer via gelatin-coated stents prevents in-stent thrombosis. Arterioscler Thromb Vasc Biol 2009 0.79
45 Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Clin Exp Nephrol 2014 0.79
46 Paucity of CD34-positive cells and increased expression of high-mobility group box 1 in coronary thrombus with type 2 diabetes mellitus. Atherosclerosis 2012 0.79
47 Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis. Thromb Haemost 2009 0.79
48 Cilostazol down-regulates the height of mural platelet thrombi formed under a high-shear rate flow in the absence of ADAMTS13 activity. Eur J Pharmacol 2012 0.79
49 Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. Liver Transpl 2006 0.79
50 Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy. Pediatr Int 2015 0.79
51 Atypical haemolytic uraemic syndrome in a Japanese patient with DGKE genetic mutations. Thromb Haemost 2015 0.79
52 Decreased ADAMTS13 levels in patients after living donor liver transplantation. Thromb Res 2009 0.78
53 ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment. Transfusion 2013 0.78
54 [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity]. Rinsho Byori 2015 0.78
55 ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score. Hepatol Res 2012 0.78
56 Von Willebrand factor--cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report. Liver Transpl 2003 0.78
57 ADAMTS13 activity decreases after hepatectomy, reflecting a postoperative liver dysfunction. Hepatogastroenterology 2010 0.78
58 Therapeutic modality of 11 patients with TTP in a single institution in Miyazaki from 2000 to 2011. Intern Med 2013 0.78
59 [Shear stress-induced platelet aggregation in children with minimal change nephrotic syndrome]. Nihon Jinzo Gakkai Shi 2002 0.78
60 Quantitative Western blot analysis of plasma ADAMTS13 antigen in patients with Upshaw-Schulman syndrome. Thromb Res 2006 0.78
61 Case of maternal and fetal deaths due to severe congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) during pregnancy. J Obstet Gynaecol Res 2013 0.77
62 Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2005 0.77
63 Proteolytic fragmentation and sugar chains of plasma ADAMTS13 purified by a conformation-dependent monoclonal antibody. J Biochem 2010 0.77
64 Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR). Br J Haematol 2013 0.77
65 [Von Willebrand factor-cleaving protease activity in patients of collagen disease with antiphospholipid antibodies]. Rinsho Byori 2002 0.77
66 Potential role of ADAMTS13 in the progression of alcoholic hepatitis. Curr Drug Abuse Rev 2008 0.77
67 [Pathophysiology of thrombotic thrombocytopenic purpura]. Nihon Jinzo Gakkai Shi 2014 0.76
68 H1N1 influenza (swine flu)-associated thrombotic microangiopathy with a markedly high plasma ratio of von Willebrand factor to ADAMTS13. Intern Med 2011 0.76
69 Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Pediatr Int 2014 0.76
70 Anticoagulant activity of M-LAO, L-amino acid oxidase purified from Agkistrodon halys blomhoffii, through selective inhibition of factor IX. Biochim Biophys Acta 2003 0.76
71 The significance of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura complicated autoimmune hepatitis. Thromb Haemost 2009 0.76
72 Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report. BMC Nephrol 2013 0.76
73 Paradigm shift of childhood thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency. Presse Med 2012 0.75
74 Response to 'Death during pregnancy: thrombotic thrombocytopenic purpura or septic shock?'. J Obstet Gynaecol Res 2013 0.75
75 Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One 2012 0.75
76 Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis. Int J Hepatol 2011 0.75
77 The homozygous p.C1024R- ADAMTS13 gene mutation links to a late-onset phenotype of Upshaw-Schulman syndrome in Japan. Thromb Haemost 2012 0.75
78 A second national questionnaire survey of TMA. Int J Hematol 2010 0.75
79 [Thrombotic thrombocytopenic purpura]. Rinsho Ketsueki 2012 0.75
80 [Progress on TTP/HUS diagnosis with analysis of VWF-cleaving protease activation]. Nihon Naika Gakkai Zasshi 2004 0.75
81 [vWF-cleaving protease/ADAMTS 13]. Rinsho Ketsueki 2003 0.75
82 [Thrombotic microangiopathy]. Rinsho Ketsueki 2006 0.75
83 National questionnaire survey of TMA. Int J Hematol 2009 0.75
84 Successful treatment of primitive neuroectodermal tumor-associated microangiopathy with multiple bone metastases. Jpn J Clin Oncol 2006 0.75
85 [Changes of ADAMTS13 activity and endothelial cell markers in TMA cases]. Rinsho Ketsueki 2004 0.75
86 Correction: A Novel Quantitative Hemolytic Assay Coupled with Restriction Fragment Length Polymorphisms Analysis Enabled Early Diagnosis of Atypical Hemolytic Uremic Syndrome and Identified Unique Predisposing Mutations in Japan. PLoS One 2017 0.75
87 [Atypical hemolytic uremic syndrome]. Rinsho Ketsueki 2013 0.75
88 Two newborn-onset patients of Upshaw-Schulman syndrome with distinct subsequent clinical courses. Int J Hematol 2012 0.75
89 [Refractory thrombotic thrombocytopenic purpura successfully treated with a combination of rituximab and vincristine]. Rinsho Ketsueki 2007 0.75
90 Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): important discrimination from Upshaw-Schulman syndrome. Am J Hematol 2002 0.75
91 Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. Thromb Res 2006 0.75
92 Limited renal prophylaxis in regular plasmatherapy for heritable ADAMTS13 deficiency. Pediatr Blood Cancer 2013 0.75
93 Forty-two-day-old boy with acute idiopathic thrombocytopenic purpura. Pediatr Int 2010 0.75
94 [Rituximab provided long-term remission in a patient with severe thrombotic thrombocytopenic purpura refractory to plasma exchange]. Rinsho Ketsueki 2006 0.75
95 Von Willebrand factor-cleaving protease activity remains at the intermediate level in thrombotic thrombocytopenic purpura. Acta Haematol 2005 0.75
96 [Case report; successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura]. Nihon Naika Gakkai Zasshi 2013 0.75
97 [Brain nerve symptoms due to thrombotic microangiopathy]. Nihon Naika Gakkai Zasshi 2007 0.75
98 Reduced larger von Willebrand factor multimers at dawn in OSA plasmas reflect severity of apnoeic episodes. Eur Respir J 2012 0.75
99 [Thrombosis and ADAMTS13 exclusively produced in the liver]. Rinsho Ketsueki 2008 0.75
100 A 9-month-old infant with acquired idiopathic thrombotic thrombocytopenic purpura caused by inhibitory IgG-autoantibody to ADAMTS13. Pediatr Hematol Oncol 2010 0.75
101 Pediatric idiopathic TTP diagnosed with decreased ADAMTS13 activity. Pediatr Int 2012 0.75
102 Identification and recombinant analysis of botrocetin-2, a snake venom cofactor for von Willebrand factor-induced platelet agglutination. Biochemistry 2012 0.75
103 Intensive plasma IgG removal therapy for severe thrombotic thrombocytopenic purpura. Int J Hematol 2002 0.75
104 [Diagnostic criteria of atypical hemolytic uremic syndrome]. Nihon Jinzo Gakkai Shi 2013 0.75
105 [Recent therapeutic strategy for thrombotic thrombocytopenic purpura]. Rinsho Ketsueki 2014 0.75
106 A novel Wiskott-Aldrich syndrome protein mutation in an infant with thrombotic thrombocytopenic purpura. Eur J Haematol 2013 0.75
107 [TTP/HUS and VWF/ADAMTS-13]. Rinsho Ketsueki 2003 0.75
108 Chemotherapy-resistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab. Int J Hematol 2008 0.75